CEL-SCI Advances Multikine Toward Market with FDA Registration Study
Event summary
- CEL-SCI launches global Phase 3 confirmatory study for Multikine in head and neck cancer, targeting FDA registration.
- Study enrolls 212 patients with low/zero PD-L1 expression, optimized for 97% statistical power to detect hazard ratio of 0.34.
- Orient EuroPharma funds patient enrollment in Taiwan as part of strategic partnership.
- Prior Phase 3 data showed 73% five-year survival vs. 45% with standard care in target cohort.
The big picture
This confirmatory study represents a critical step in validating Multikine's survival benefit in a precisely defined patient population, addressing an unmet need in head and neck cancer where long-term outcomes have plateaued despite advances in conventional therapies. The neoadjuvant immunotherapy approach targets patients before immune system compromise from standard treatments, potentially creating a new treatment paradigm.
What we're watching
- Regulatory Pathway
- Whether accelerated approval can be pursued based on early endpoints while awaiting overall survival data.
- Execution Risk
- The pace at which global enrollment proceeds across U.S., Europe, Asia, and South America.
- Commercial Strategy
- How CEL-SCI positions Multikine as standard of care for PD-L1 low/zero head and neck cancer patients.
Related topics